Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 60

Sort by

Sort Order Select

Journal Articles

A phase 1 clinical trial of NKTR-255 with CD19-22 CAR T-cell therapy for refractory B-cell acute lymphoblastic leukemia

Blood (2024) 144 (16): 1689–1698.

https://doi.org/10.1182/blood.2024024952

Published: 2024

Includes: Supplemental data

Journal Articles

CAR19 Therapy Drives Expansion of Clonal Hematopoiesis and Associated Cytopenias

Blood (2023) 142 (Supplement 1): 360.

https://doi.org/10.1182/blood-2023-182522

Published: 2023

Journal Articles

Impact of Obesity on Efficacy, Safety, and Expansion Kinetics of Chimeric Antigen Receptor-T (CAR T) Therapy in Patients with Relapsed or Refractory Large B Cell Lymphoma (LBCL)

Anmol Goyal, Sushma Bharadwaj, Dasom Lee, Eric Lau, Mark P. Hamilton, Alexandria Jensen, Bita Sahaf, Shriya Syal, Sunita Patil, Juancarlos E Cancilla, Theresa Latchford, Wen-Kai Weng, Melody Smith, Matthew J. Frank, David B. Miklos, Saurabh Dahiya

Blood (2023) 142 (Supplement 1): 3783.

https://doi.org/10.1182/blood-2023-186828

Published: 2023

Journal Articles

Transcriptional Profiling Associated with CD22 CAR T Cell Clinical Response in LBCL

Blood (2023) 142 (Supplement 1): 2091.

https://doi.org/10.1182/blood-2023-187615

Published: 2023

Journal Articles

Manufacturing of a Subsequent Autologous CAR-T Product after Prior CAR-T Is Safe and Feasible

Yi-Jiun Su, Anne Marijn Kramer, Mark P. Hamilton, Neha Agarwal, Steven Feldman, Bita Sahaf, Adam Kuo, Crystal L. Mackall, Lori S. Muffly, David B. Miklos, Matthew J. Frank

Blood (2023) 142 (Supplement 1): 1037.

https://doi.org/10.1182/blood-2023-185413

Published: 2023

Journal Articles

Comparative Effectiveness of Axicabtagene Ciloleucel Vs Historical Standard-of-Care in Patients with Relapsed or Refractory Follicular Lymphoma: An Analysis of CIBMTR and SCHOLAR-5 Data

Blood (2023) 142 (Supplement 1): 2121.

https://doi.org/10.1182/blood-2023-178629

Published: 2023

Journal Articles

Second-Line Chimeric Antigen Receptor T Cell Therapy (CAR-T) As Standard of Care for Relapsed-Refractory Large B-Cell Lymphoma (LBCL)

Saurabh Dahiya, Jay Y. Spiegel, Dasom Lee, Turab Mohammed, Forat Lutfi, Anmol Goyal, Caroline Hana, Julio C Chavez, Filip Ionescu, Matthew J. Frank, Sushma Bharadwaj, Jose Sandoval-Sus, Amer M. Beitinjaneh, Lazaros J. Lekakis, Joseph P McGuirk, Frederick L. Locke, David B. Miklos, Michael D. Jain

Blood (2023) 142 (Supplement 1): 4876.

https://doi.org/10.1182/blood-2023-188918

Published: 2023

Journal Articles

Post-CAR-T Minimal Residual Disease (MRD) Monitoring in Mantle Cell Lymphoma Enables Early Relapse Detection

Snegha Ananth, Yi-Jiun Su, Mark P. Hamilton, Neha Agarwal, Wen-Kai Weng, Saurabh Dahiya, Sushma Bharadwaj, Jayasindhu Mallampet, Melody Smith, Katherine Ann Kong, Abigail Twoy, David B. Miklos, Matthew J. Frank

Blood (2023) 142 (Supplement 1): 1673.

https://doi.org/10.1182/blood-2023-188338

Published: 2023

Journal Articles

Phase 1 Trial Results for Patients with Advanced Hematologic Malignancies Undergoing Reduced Intensity Allogeneic HCT with Orca-T Donor Cell Therapy Product and Single Agent Tacrolimus

Blood (2023) 142 (Supplement 1): 3560.

https://doi.org/10.1182/blood-2023-188162

Published: 2023

Journal Articles

CD22 CAR T Cell-Related IEC-HS Is Associated with an IFN-γ Cytokine Signature

Hrishikesh Srinagesh, John H. Baird, Neha Agarwal, Yi-Jiun Su, Anne Marijn Kramer, Agnes Reschke, Nikeshan Jeyakumar, Sushma Bharadwaj, Liora Michal Schultz, Sneha Ramakrishna, Kara L. Davis, Bita Sahaf, Steven Feldman, Crystal L. Mackall, David B. Miklos, Lori S. Muffly, Matthew J. Frank

Blood (2023) 142 (Supplement 1): 4839.

https://doi.org/10.1182/blood-2023-178283

Published: 2023

Journal Articles

Analysis of PET-CT Derived Radiomic Biomarkers with Efficacy, Safety, and Expansion of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL)

Blood (2023) 142 (Supplement 1): 2125.

https://doi.org/10.1182/blood-2023-187617

Published: 2023

Journal Articles

Long-Term Efficacy and Immune Reconstitution with Bendamustine As a Lymphodepleting Agent for Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory or Relapsed Large B-Cell Lymphoma (LBCL)

Sushma Bharadwaj, Eric Lau, Anmol Goyal, Mark P. Hamilton, Hrishikesh Srinagesh, Alexandria Jensen, Shriya Syal, Jayasindhu Mallampet, Theresa Latchford, Bita Sahaf, Wen-Kai Weng, Melody Smith, Holden T Maecker, Matthew J. Frank, David B. Miklos, Saurabh Dahiya

Blood (2023) 142 (Supplement 1): 4878.

https://doi.org/10.1182/blood-2023-188166

Published: 2023

Journal Articles

Improved outcomes for relapsed/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents

Michael A. Spinner, R. A. Sica, John S. Tamaresis, Ying Lu, Cheryl Chang, Robert Lowsky, Matthew J. Frank, Laura J. Johnston, David B. Miklos, Lori S. Muffly, Robert S. Negrin, Andrew R. Rezvani, Parveen Shiraz, Judith A. Shizuru, Wen-Kai Weng, Michael S. Binkley, Richard T. Hoppe, Ranjana H. Advani, Sally Arai

Blood (2023) 141 (22): 2727–2737.

https://doi.org/10.1182/blood.2022018827

Published: 2023

Includes: Supplemental data

Journal Articles

Activating Immune Effectors and Dampening Immune Suppressors Generates Successful Therapeutic Cancer Vaccination in Patients with Lymphoma

Tanaya Shree, Sarah Haebe, Debra K. Czerwinski, Erik Eckhert, Grady Day, Anuja Sathe, Susan M. Grimes, Matthew J Frank, Lauren S. Maeda, Ash A. Alizadeh, Ranjana H. Advani, Richard Hoppe, Steven R. Long, Brock Martin, Michael G. Ozawa, Michael S. Khodadoust, Hanlee P. Ji, Ronald Levy

Blood (2022) 140 (Supplement 1): 6450–6451.

https://doi.org/10.1182/blood-2022-167469

Published: 2022

Journal Articles

CD22 CAR T Cells Demonstrate Favorable Safety Profile and High Response Rates in Pediatric and Adult B-ALL: Results of a Phase 1b Study

Nikeshan Jeyakumar, Sneha Ramakrishna, Matthew J Frank, Bita Sahaf, Steven A. Feldman, David B. Miklos, Crystal L. Mackall, Kara L. Davis, Lori Muffly, Liora M. Schultz

Blood (2022) 140 (Supplement 1): 2374–2375.

https://doi.org/10.1182/blood-2022-164456

Published: 2022

Journal Articles

Clonal Hematopoiesis Driven By Recurrent Somatic Mutations but Not with Recurrent Copy Number Alterations Is Associated with Inferior Outcomes in DLBCL after Induction Chemotherapy, but Not CAR19 Therapy

Jan Boegeholz, Stefan K. Alig, Brian Sworder, Joseph Schroers-Martin, Charles Macaulay, Alexander F.M. Craig, Ulrich Duehrsen, Andreas Hüttmann, Jason Westin, Hua-Jay J. Cherng, David B. Miklos, Matthew J Frank, Maximilian Diehn, David M. Kurtz, Ash A. Alizadeh

Blood (2022) 140 (Supplement 1): 8609–8610.

https://doi.org/10.1182/blood-2022-170087

Published: 2022

Journal Articles

Long-Term Cognitive and Neuropsychiatric Outcomes in Adults Who Have Received Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Aggressive Lymphoma at Stanford - a Pilot Feasibility Study

Brian J Scott, Tracy Murray, Gayle K Deutsch, Sheila Lahijani, Matthew J Frank, Michelle Monje

Blood (2022) 140 (Supplement 1): 5201–5202.

https://doi.org/10.1182/blood-2022-168229

Published: 2022

Journal Articles

Long-Term Follow-up of CD19/22 CAR Therapy in Children and Young Adults with B-ALL Reveals Efficacy, Tolerability and High Survival Rates When Coupled with Hematopoietic Stem Cell Transplantation

Blood (2022) 140 (Supplement 1): 10300–10302.

https://doi.org/10.1182/blood-2022-167789

Published: 2022

Journal Articles

Higher Rates of Severe Infection and Persistent Cytopenias in Long-Term CAR19 Responders Than after Autologous HCT: A Single Institution Study of 139 Subjects

Blood (2022) 140 (Supplement 1): 7545–7547.

https://doi.org/10.1182/blood-2022-165600

Published: 2022

Journal Articles

Specificity & Precision of Minimal Residual Disease Monitoring in DLBCL Using Ig-HTS

Navika D. Shukla, Joseph Schroers-Martin, Karan R. Kathuria, Brian Sworder, Stefan K. Alig, Matthew J Frank, David B. Miklos, Steven Coutre, Maximilian Diehn, Michael S. Khodadoust, Mark Roschewski, David M. Kurtz, Ash A. Alizadeh

Blood (2022) 140 (Supplement 1): 6403–6404.

https://doi.org/10.1182/blood-2022-165656

Published: 2022

NARROW

A phase 1 clinical trial of NKTR-255 with CD19-22 CAR T-cell therapy for refractory B-cell acute lymphoblastic leukemia

CAR19 Therapy Drives Expansion of Clonal Hematopoiesis and Associated Cytopenias

Impact of Obesity on Efficacy, Safety, and Expansion Kinetics of Chimeric Antigen Receptor-T (CAR T) Therapy in Patients with Relapsed or Refractory Large B Cell Lymphoma (LBCL)

Transcriptional Profiling Associated with CD22 CAR T Cell Clinical Response in LBCL

Manufacturing of a Subsequent Autologous CAR-T Product after Prior CAR-T Is Safe and Feasible

Comparative Effectiveness of Axicabtagene Ciloleucel Vs Historical Standard-of-Care in Patients with Relapsed or Refractory Follicular Lymphoma: An Analysis of CIBMTR and SCHOLAR-5 Data

Second-Line Chimeric Antigen Receptor T Cell Therapy (CAR-T) As Standard of Care for Relapsed-Refractory Large B-Cell Lymphoma (LBCL)

Post-CAR-T Minimal Residual Disease (MRD) Monitoring in Mantle Cell Lymphoma Enables Early Relapse Detection

Phase 1 Trial Results for Patients with Advanced Hematologic Malignancies Undergoing Reduced Intensity Allogeneic HCT with Orca-T Donor Cell Therapy Product and Single Agent Tacrolimus

CD22 CAR T Cell-Related IEC-HS Is Associated with an IFN-γ Cytokine Signature

Analysis of PET-CT Derived Radiomic Biomarkers with Efficacy, Safety, and Expansion of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL)

Long-Term Efficacy and Immune Reconstitution with Bendamustine As a Lymphodepleting Agent for Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory or Relapsed Large B-Cell Lymphoma (LBCL)

Improved outcomes for relapsed/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents

Activating Immune Effectors and Dampening Immune Suppressors Generates Successful Therapeutic Cancer Vaccination in Patients with Lymphoma

CD22 CAR T Cells Demonstrate Favorable Safety Profile and High Response Rates in Pediatric and Adult B-ALL: Results of a Phase 1b Study

Clonal Hematopoiesis Driven By Recurrent Somatic Mutations but Not with Recurrent Copy Number Alterations Is Associated with Inferior Outcomes in DLBCL after Induction Chemotherapy, but Not CAR19 Therapy

Long-Term Cognitive and Neuropsychiatric Outcomes in Adults Who Have Received Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Aggressive Lymphoma at Stanford - a Pilot Feasibility Study

Long-Term Follow-up of CD19/22 CAR Therapy in Children and Young Adults with B-ALL Reveals Efficacy, Tolerability and High Survival Rates When Coupled with Hematopoietic Stem Cell Transplantation

Higher Rates of Severe Infection and Persistent Cytopenias in Long-Term CAR19 Responders Than after Autologous HCT: A Single Institution Study of 139 Subjects

Specificity & Precision of Minimal Residual Disease Monitoring in DLBCL Using Ig-HTS

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only